HC Wainwright Issues Positive Forecast for ARTV Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – HC Wainwright boosted their Q1 2025 earnings estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their previous forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

ARTV has been the subject of a number of other research reports. Wedbush restated an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. Cantor Fitzgerald reduced their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $20.40.

Artiva Biotherapeutics Stock Down 10.7 %

Shares of Artiva Biotherapeutics stock opened at $3.16 on Friday. The stock’s fifty day moving average is $4.71 and its 200 day moving average is $9.23. Artiva Biotherapeutics has a one year low of $3.15 and a one year high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARTV. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Artiva Biotherapeutics during the fourth quarter worth $52,000. Wells Fargo & Company MN grew its stake in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares in the last quarter. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Finally, JPMorgan Chase & Co. purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.